drugset / Trial / NCT05597306
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
18 enrolled
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2022-11-19
- Primary completion
- 2026-11-19
- Completion
- 2026-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bomedemstat | Small molecule | 0.375 mg/kg | Oral |
| Subject | Bomedemstat | Small molecule | 0.75 mg/kg | Oral |
| Subject | Bomedemstat | Small molecule | 1.5 mg/kg | Oral |
| Subject | Bomedemstat | Small molecule | 3 mg/kg | Oral |
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |